Home

en Visión infinito nkg2a blocking antibody Tiranía ajedrez tiempo

Frontiers | NK Cell-Based Immune Checkpoint Inhibition
Frontiers | NK Cell-Based Immune Checkpoint Inhibition

A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells | PLOS Pathogens
A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells | PLOS Pathogens

NKG2A is a NK cell exhaustion checkpoint for HCV persistence | Nature Communications
NKG2A is a NK cell exhaustion checkpoint for HCV persistence | Nature Communications

Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies | Journal of the American Society for Mass Spectrometry
Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies | Journal of the American Society for Mass Spectrometry

JCI - Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
JCI - Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

Natural Killer Cell Receptor NKG2A - an overview | ScienceDirect Topics
Natural Killer Cell Receptor NKG2A - an overview | ScienceDirect Topics

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy | Signal Transduction and Targeted Therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy | Signal Transduction and Targeted Therapy

Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program - Creative Biolabs
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program - Creative Biolabs

HLA-E and NKG2A as a novel immune checkpoint axis to improve treatment for non-muscle invasive bladder cancer | Horowitz Laboratory
HLA-E and NKG2A as a novel immune checkpoint axis to improve treatment for non-muscle invasive bladder cancer | Horowitz Laboratory

NKG2A, a New Kid on the Immune Checkpoint Block - ScienceDirect
NKG2A, a New Kid on the Immune Checkpoint Block - ScienceDirect

Frontiers | NK Cell Dysfunction and Checkpoint Immunotherapy
Frontiers | NK Cell Dysfunction and Checkpoint Immunotherapy

Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment | Journal for ImmunoTherapy of Cancer | Full Text
Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment | Journal for ImmunoTherapy of Cancer | Full Text

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board: Trends in Immunology
Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board: Trends in Immunology

NKG2A is a NK cell exhaustion checkpoint for HCV persistence | Nature Communications
NKG2A is a NK cell exhaustion checkpoint for HCV persistence | Nature Communications

JCI - Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
JCI - Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program - Creative Biolabs
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program - Creative Biolabs

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells - ScienceDirect
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells - ScienceDirect

NKG2A/CD159a/KLRC1 Antibody (131411) [Unconjugated] (MAB1059): Novus Biologicals
NKG2A/CD159a/KLRC1 Antibody (131411) [Unconjugated] (MAB1059): Novus Biologicals

Recombinant Anti-NKG2A antibody [EPR23737-127] (ab260035) | Abcam
Recombinant Anti-NKG2A antibody [EPR23737-127] (ab260035) | Abcam

NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions
NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions

Discovery and pre-clinical evaluation of antibodies to the NKG2A inhibitory receptor | bioRxiv
Discovery and pre-clinical evaluation of antibodies to the NKG2A inhibitory receptor | bioRxiv

Frontiers | Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
Frontiers | Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A

Effect of NKG2A expression on natural killer (NK) cells on NK cell... | Download Scientific Diagram
Effect of NKG2A expression on natural killer (NK) cells on NK cell... | Download Scientific Diagram

Receptor interaction of HLA-E with NKG2A, -B/CD94 and NKG2C/CD94. HLA-E... | Download Scientific Diagram
Receptor interaction of HLA-E with NKG2A, -B/CD94 and NKG2C/CD94. HLA-E... | Download Scientific Diagram

Blocking the Natural Killer Cell Inhibitory Receptor NKG2A Increases Activity of Human Natural Killer Cells and Clears Hepatitis B Virus Infection in Mice - Gastroenterology
Blocking the Natural Killer Cell Inhibitory Receptor NKG2A Increases Activity of Human Natural Killer Cells and Clears Hepatitis B Virus Infection in Mice - Gastroenterology

NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer - ScienceDirect
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer - ScienceDirect

NKG2A blockade releases the brakes on CD8+ T cells and NK cells
NKG2A blockade releases the brakes on CD8+ T cells and NK cells